Acadia Pharmaceuticals (ACAD) Other Non Operating Income (2018 - 2026)

Acadia Pharmaceuticals' Other Non Operating Income history runs 9 years deep, the most recent figure standing at $542000.0 for Q1 2026.

• In Q1 2026, Other Non Operating Income fell 7.82% year-over-year to $542000.0; the TTM figure through Mar 2026 stood at $10.6 million (up 396.66% YoY), while the FY2025 annual figure was $10.6 million, up 481.46% from the prior year.
• Other Non Operating Income for Q1 2026 stood at $542000.0, down from $8.8 million in the prior quarter.
• The five-year high for Other Non Operating Income was $8.8 million in Q4 2025, with the low at -$4.0 million in Q4 2022.
• The 5-year median for Other Non Operating Income is $576000.0 (2024), against an average of $989470.6.
• The sharpest annual moves came in 2022 and 2025: Other Non Operating Income plunged 379.21% in 2022, then jumped 1434.78% in 2025.
• Acadia Pharmaceuticals' Other Non Operating Income stood at -$4.0 million in 2022, then surged by 118.09% to $718000.0 in 2023, then decreased by 19.92% to $575000.0 in 2024, then surged by 1434.78% to $8.8 million in 2025, then tumbled by 93.86% to $542000.0 in 2026.
• Business Quant data shows ACAD's Other Non Operating Income at $542000.0 in Q1 2026, $8.8 million in Q4 2025, and $593000.0 in Q3 2025.